The weight-loss drug Ozempic can help reduce stroke patients' risk of a heart attack or death, a new study says.
New study reports protective effect among people with type 2 diabetes Kidney stones and the systemic conditions associated with them have a major impact on health and the economy in the US and ...
GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the risk of heart attack, second strokes and death ...
Of note, a similar proportion of patients in the empagliflozin and placebo groups (43% and 40%, respectively) were using an ...
A recent case report highlights the importance of understanding the possibility of the development of Euglycemic diabetic ...
Sodium-glucose cotransporter 2 (SGLT2) inhibitors may protect the kidneys better than glucagon-like peptide 1 receptor ...
Treatment with sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors) is associated with a lower mortality risk in older patients with advanced chronic kidney disease (CKD), according to data ...
The use of SGLT2 inhibitors was associated with a significantly reduced risk for dementia and PD in patients with type 2 diabetes.
Geroscience has a long way to go, but there are four FDA-approved drugs that have shown promise to “target the process of ...
Patients with broad range of kidney function show reduced effects following discontinuation after EMPA-KIDNEY trial.
Sodium-glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of cardiovascular and kidney outcomes in patients with type 2 diabetes, but it is unclear whether their effects differ based on ...